Atrovent Hfa

Atrovent HFA by Boehringer Ingelheim treats COPD, improving airflow and reducing symptoms. It contains ipratropium bromide, a bronchodilator that relaxes airway muscles for easier breathing, typically used as part of a comprehensive respiratory management plan.

Manufacturer

Boehringer Ingelheim Pharmaceuticals Inc

Formulation

inhalation / aerosol, metered

Active: ipratropium bromide

Approved

11/27/2004

Expires

1/17/2030

ACNU Feasibility

View full report

Atrovent HFA is a generally safe anticholinergic inhaler with mild side effects, low misuse risk, minimal drug interactions, and simple dosing. It requires occasional monitoring and has good adherence, with caution advised for certain populations like those with glaucoma or prostate issues.